HIMS
🚀 Hims & Hers Health reported exceptionally positive Q1 results, with revenue soaring over 110% to more than $586 million and achieving a net income of nearly $50 million.
📈 The company raised its 2025 adjusted EBITDA forecast to between $295 million and $335 million, while maintaining its revenue guidance of $2.3 to $2.4 billion.
⚠️ Despite strong growth, Hims experienced a slight contraction in margins, and its Q2 adjusted EBITDA guidance ($60-70 million) indicates a sequential decrease, which appeared to concern the market.
@bernardodegarcia:
“I wanted to talk about HIMS. There it is. HIMS reported exceptionally positive financial results in the first quarter, with revenues increasing more than 110% to over $586 million. The company achieved a net income of almost $50 million, about $49.5 million, and an adjusted EBITDA of $91.1 million. The subscriber base grew 38% year-over-year, with average monthly online revenue per subscriber increasing by 53%. The company maintained its revenue guidance for 2025 between $2.3 and $2.4 billion and raised its adjusted EBITDA forecast to between $295 and $335 million. Ah, the downside is that margins contracted a bit, and that seems to be something the markets are not liking. Hims presented ambitious targets, as we know, for 2030: at least $6.5 billion in revenue and $1.3 billion in adjusted EBITDA. For this second quarter, the company expects revenue of $530 to $550 million and an adjusted EBITDA of $60 to $70 million, a small contraction compared to these quarterly results.”
Watch the exact part of the video where Bernardo de Garcia talks about Hims & Hers Health here:
Watch the video on YouTube
Read more articles by the world’s top 100 analysts on Hims & Hers Health (HIMS) at the following link. HIMS stock.
